Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04448886 · ClinicalTrials.gov registry record · Phase 2

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

A Phase 2 study of Metastatic Breast Cancer and HER2-Negative Breast Cancer, sponsored by Ana C Garrido-Castro, MD.

Active
Registry status
Phase 2
Development phase
110
Enrollment target
8
Study locations

NCT04448886 is a Phase 2 study of Metastatic Breast Cancer and HER2-Negative Breast Cancer that is active but no longer recruiting, run by Ana C Garrido-Castro, MD. The registered enrollment target is 110 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (46% lower). The trial reports 8 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04448886, a Phase 2 study of Metastatic Breast Cancer and HER2-Negative Breast Cancer, is active but no longer recruiting, sponsored by Ana C Garrido-Castro, MD.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
110 participants
Enrollment target
8
Study locations

Study Summary

This research study is evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer. The names of the study interventions involved in this study are: * Sacituzumab govitecan (IMMU-132) * Pembrolizumab (Keytruda®; MK-3475)

Conditions Studied

Metastatic Breast Cancer HER2-Negative Breast Cancer Invasive Breast Cancer HR-Positive Breast Cancer

Interventions

  • DRUG Pembrolizumab
  • DRUG Sacituzumab Govitecan

Study Locations (8)

Massachusetts

  • Dana Farber Cancer Institute - Boston
  • DFCI @ Foxborough - Foxborough
  • DFCI @ Milford Regional Hospital - Milford
  • DF/BWCC in Clinical Affiliation with South Shore Hospital - South Weymouth

Georgia

  • Emory University/Winship Cancer Institute - Atlanta

Illinois

  • University of Chicago Medical Center - Chicago

North Carolina

  • University of North Carolina at Chapel Hill - Chapel Hill

Pennsylvania

  • University of Pennsylvania-Abramson Cancer Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2020-09-23
Est. Completion 2027-06-01
Phase Phase 2

Sponsor

Ana C Garrido-Castro, MD

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04448886

The ClinicalTrials.gov registry entry for NCT04448886 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (46% lower). The listed sponsor is Ana C Garrido-Castro, MD, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT04448886 reports 8 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, Georgia, Illinois.

Frequently Asked Questions

What is clinical trial NCT04448886 about?

NCT04448886 is a clinical study titled "Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC". This research study is evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer. The names of the study interventions involved in this study are: * Sacituzumab govitecan (IMMU-132) * Pembrolizumab (Keytruda®; MK-3475)

What is the current status of trial NCT04448886?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2020-09-23. Estimated completion is 2027-06-01.

What conditions does trial NCT04448886 study?

This clinical trial studies the following conditions: Metastatic Breast Cancer, HER2-Negative Breast Cancer, Invasive Breast Cancer, HR-Positive Breast Cancer.

What interventions are being tested in trial NCT04448886?

The interventions under investigation include: Pembrolizumab (DRUG), Sacituzumab Govitecan (DRUG).

Who is sponsoring clinical trial NCT04448886?

This trial is sponsored by Ana C Garrido-Castro, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04448886 being conducted?

This trial has 8 study locations across Georgia, Illinois, Massachusetts, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Breast Cancer

All registered trials for this condition

HER2-Negative Breast Cancer

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.